干眼症治疗 - 全球行业规模、份额、趋势、机遇和预测，2018-2028 年：按适应症、按产品类型、按配方、按类型、按分销渠道、按地区、按竞争

在预测期内，干眼症治疗的全球市场预计将出现显着增长。

这是由于某些疾病（例如类风湿性关节炎、甲状腺疾病和狼疮）导致全球干眼症的患病率不断上升。 此外，新眼药水的批准和上市增加，医疗保健领域为开髮干眼病新疗法而增加的研发活动也有望在预测期内进一步支持干眼症治疗市场的增长。 美国有超过12万人因青光眼失明，占失明病例的9%至12%。 此外，增加成人泪液产生的鼻内泪腺神经刺激器的开发正在取得进展，预计随着新疗法的开发，这将在预测期内推动市场增长。 此外，随着监管审批的增加，市场新进入者的增加预计将进一步推动市场增长。

干眼症患病率增加

最常见的干眼病是一种慢性眼科疾病，与成年人相比，它在老年人群中的患病率更高。 屏幕使用频率增加、饮食摄入不当、隐形眼镜使用频率增加以及全球 LASIK 手术数量增加将进一步推动预测期内的市场增长。 随着年龄的增长，泪腺产生泪液的能力下降，导致干眼症，导致对干眼症的需求，并成为预测期内推动市场增长的关键因素之一。。 根据国家健康与健康调查的数据，6.8% 的美国成年人（约 1640 万人）被诊断出患有 DED。

加大对医疗保健行业的投资

此外，增加公共和私营部门的举措以传播对干眼症新疗法的认识，这将推动干眼症治疗市场多年发展。 饮食习惯和久坐不动的生活方式的改变是影响预测期内市场动态的因素。 全球眼科护理中心的发展以及 OTC 眼药水市场在发展中地区的渗透率不断提高，将进一步推动预测期内的市场增长。 2022年1月，Sun Pharma宣布将在加拿大推出名为Cequa的干眼症治疗产品。 这是第一种使用纳米胶束 (NCELL) 技术进行的干眼病治疗。 该技术不仅提高了环孢菌素的生物利用度，还提高了理化稳定性和对眼组织的渗透性。

近期发展

• 2019 年 10 月，Sun Pharmaceutical Industries Ltd 在美国推出了干眼症治疗药物 CEQUA，是美国 FDA 批准的最高浓度眼用环孢菌素。
• 2019 年 7 月 Novartis是第一个也是唯一一个获批通过控制干眼症特异性炎症来治疗干眼症症状和体征的处方药。宣布成功收购 Xiidra 5%

可自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

• 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析。

内容

第 1 章概述

• 市场定义
• 市场范围
  • 目标市场
  • 研究目标年份
  • 主要市场细分

第二章研究方法论

• 调查目的
• 基线调查方法
• 主要行业合作伙伴
• 主要协会和次要信息
• 调查方法
• 数据三角测量和验证
• 假设和限制

第 3 章执行摘要

• 市场概览
• 主要市场细分概述
• 主要市场参与者概览
• 主要地区/国家概览
• 市场驱动因素、挑战和趋势

第 4 章 VOC（客户之声）

第5章临床试验分析

• 正在进行的临床试验
• 已完成临床试验
• 已完成临床试验
• 管道细分（按开发阶段）
• 管道细分（按状态）
• 管道细分（按研究类型）
• 按地区划分的渠道细分
• 临床试验热图

第 6 章干眼症治疗的全球市场展望

• 市场规模和预测
  • 按数量
• 市场份额和预测
  • 根据适应症（蒸发过强性干眼症/房水性干眼症）
  • 按产品类型（环孢菌素、皮质类固醇、人工泪液、穿刺塞等）
  • 按剂型（凝胶剂、眼药水、胶囊/片剂、滴眼剂、软膏）
  • 按类型（处方药/非处方药）
  • 按分销渠道（医院药店、零售药店、在线药店）
  • 按地区
  • 按公司分类（2022 年）
• 市场地图
  • 按视图
  • 按产品类型
  • 按剂型
  • 按类型
  • 按分销渠道
  • 按地区

第 7 章北美干眼症治疗市场展望

• 市场规模和预测
  • 按数量
• 市场份额和预测
  • 按视图
  • 按产品类型
  • 按剂型
  • 按类型
  • 按分销渠道
  • 按国家
• 北美：国家/地区分析
  • 美国
  • 加拿大
  • 墨西哥

第 8 章欧洲干眼症治疗市场展望

• 市场规模和预测
  • 按数量
• 市场份额和预测
  • 按视图
  • 按产品类型
  • 按剂型
  • 按类型
  • 按分销渠道
  • 按国家
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 意大利
  • 西班牙

第 9 章亚太干眼症治疗市场展望

• 市场规模和预测
  • 按数量
• 市场份额和预测
  • 按视图
  • 按产品类型
  • 按剂型
  • 按类型
  • 按分销渠道
  • 按国家
• 亚太地区：国家/地区分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳大利亚

第 10 章南美干眼症治疗市场展望

• 市场规模和预测
  • 按数量
• 市场份额和预测
  • 按视图
  • 按产品类型
  • 按剂型
  • 按类型
  • 按分销渠道
  • 按国家
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章中东和非洲干眼症治疗市场展望

• 市场规模和预测
  • 按数量
• 市场份额和预测
  • 按视图
  • 按产品类型
  • 按剂型
  • 按类型
  • 按分销渠道
  • 按国家
• MEA：国家分析
  • 南非的干眼症治疗
  • 沙特阿拉伯的干眼症治疗
  • 阿联酋干眼症治疗

第 12 章市场动态

• 司机
• 任务

第13章市场趋势与发展

• 近期趋势
• 併购
• 产品发布

第14章竞争格局

• Johnson & Johnson
• AbbVie Inc.
• Bausch Health Companies Inc.
• Novartis AG
• Sun Pharmaceuticals Industries Limited
• Santen Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• Oyster Point Pharma, Inc.
• Alcon Inc.
• GlaxoSmithKline plc.

第 15 章战略建议

The Global Dry Eye Syndrome Treatment Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing prevalence of dry eye syndrome due to certain diseases, such as rheumatoid arthritis, thyroid diseases, and lupus, across the globe. Besides, increasing drug approvals and launches of new eye drops, along with rising research and development activities in the healthcare sector for the development of new treatments for dry eye diseases across the globe, are further expected to support the dry eye syndrome treatment market during the forecast period. In the U.S., more than 120,000 are blind from glaucoma, accounting for 9% to 12% of all cases of blindness. Also, the growing development of intranasal tear neurostimulation devices, which will increase tear production in adults, along with the development of new treatment modalities, will boost the market growth during the forecasted period. Also, the rising number of new players in the market is anticipated to lead the regulatory approvals and further propel the growth of the market.

Growing Prevalence of Dry Eye Disease

The most common dry eye disease is a chronic ophthalmic disorder which has a high prevalence rate among the aging population compared to adults. Growing usage of screens, consuming improper diet, growing usage of contact lenses, and the rising number of LASIK surgeries across the globe will further drive the market growth in the forecast period. Due to increasing age, the ability of the lachrymal glands to produce tears decreases, which leads to a dry eye condition which is one of the key factors contributing to the demand for dry eye syndrome and driving the growth of the market during the forecasted period. Based on data from the National Health and Wellness Survey, 6.8 percent of the United States adult population (approximately 16.4 million people) have been diagnosed with DED.

Growing investment in Healthcare Industry

Furthermore, growing initiatives by public and private organizations to spread awareness about the new treatment of dry eye syndrome will propel the dry eye syndrome treatment market over the years. Changing dietary patterns and sedentary lifestyles are the factors that will influence the market dynamics during the forecast period. Increasing the number of eye care centers across the globe and growing penetration of the OTC eyedrop market across developing regions will further boost the market growth in the forecast period. In January 2022, Sun Pharma announced the launch of a dry eye treatment product named Cequa in Canada. It is the first dry eye disease treatment that is delivered with nano micellar (NCELL) technology. This technology enhances the bioavailability as well as physiochemical stability of cyclosporine to raise ocular tissue penetration.

Market Segmentation

The Global Dry Eye Syndrome Treatment Market can be segmented by indication, product type, dosage form, type, distribution channel, and by region. Based on indication, the market can be divided into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on product type, the market can be differentiated into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and Others. Based on dosage form, the market can be grouped into Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments. Based on Type, the market can be divided into Prescription and Over Counter. Based on distribution channels, the market can be segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global dry eye syndrome treatment market on account of the growing demand for dry eye treatment in the country.

Recent Developments

• In October 2019, Sun Pharmaceutical Industries Ltd launched a product called CEQUA for the treatment of dry eye syndrome in the U.S. and the highest concentration of cyclosporine for ophthalmic use, which is approved by the U.S. FDA.

• In July 2019, Novartis announced the completion of the successful acquisition of Xiidra 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by controlling the inflammation caused by the disease.

Market Players

Johnson & Johnson, AbbVie Inc., Bausch Health Companies Inc., Novartis AG, Sun Pharmaceuticals Industries Limited, Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Alcon Inc., GlaxoSmithKline plc. are some of the leading players operating in the Global Dry Eye Syndrome Treatment Market.

Report Scope

In this report, global dry eye syndrome treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Dry Eye Syndrome Treatment Market, By Indication:

• Evaporative Dry Eye Syndrome
• Aqueous Deficient Dry Eye Syndrome

Dry Eye Syndrome Treatment Market, By Product Type:

• Cyclosporine
• Topical Corticosteroids
• Artificial Tears
• Punctal Plugs
• Others

Dry Eye Syndrome Treatment Market, By Dosage Form:

• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

Dry Eye Syndrome Treatment Market, By Type:

• Prescription
• Over The Counter

Dry Eye Syndrome Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Dry Eye Syndrome Treatment Market, By Region:

• North America
  • United States
  • Mexico
  • Canada

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Dry Eye Syndrome Treatment Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Dry Eye Syndrome Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication (Evaporative Dry Eye Syndrome v/s Aqueous Deficient Dry Eye Syndrome)
  • 6.2.2. By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Others)
  • 6.2.3. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
  • 6.2.4. By Type (Prescription v/s Over The Counter)
  • 6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.6. By Region
  • 6.2.7. By Company (2022)
• 6.3. Market Map
  • 6.3.1. By Indication
  • 6.3.2. By Product Type
  • 6.3.3. By Dosage Form
  • 6.3.4. By Type
  • 6.3.5. By Distribution Channel
  • 6.3.6. By Region

7. North America Dry Eye Syndrome Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Product Type
  • 7.2.3. By Dosage Form
  • 7.2.4. By Type
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Dry Eye Syndrome Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By Dosage Form
      • 7.3.1.2.4. By Type
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. Canada Dry Eye Syndrome Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By Dosage Form
      • 7.3.2.2.4. By Type
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. Mexico Dry Eye Syndrome Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By Dosage Form
      • 7.3.3.2.4. By Type
      • 7.3.3.2.5. By Distribution Channel

8. Europe Dry Eye Syndrome Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Product Type
  • 8.2.3. By Dosage Form
  • 8.2.4. By Type
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Dry Eye Syndrome Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By Dosage Form
      • 8.3.1.2.4. By Type
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. Germany Dry Eye Syndrome Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By Dosage Form
      • 8.3.2.2.4. By Type
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. United Kingdom Dry Eye Syndrome Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By Dosage Form
      • 8.3.3.2.4. By Type
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. Italy Dry Eye Syndrome Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Product Type
      • 8.3.4.2.3. By Dosage Form
      • 8.3.4.2.4. By Type
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Spain Dry Eye Syndrome Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Product Type
      • 8.3.5.2.3. By Dosage Form
      • 8.3.5.2.4. By Type
      • 8.3.5.2.5. By Distribution Channel

9. Asia-Pacific Dry Eye Syndrome Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Product Type
  • 9.2.3. By Dosage Form
  • 9.2.4. By Type
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Dry Eye Syndrome Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By Dosage Form
      • 9.3.1.2.4. By Type
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. India Dry Eye Syndrome Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Product Type
      • 9.3.2.2.3. By Dosage Form
      • 9.3.2.2.4. By Type
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. Japan Dry Eye Syndrome Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By Dosage Form
      • 9.3.3.2.4. By Type
      • 9.3.3.2.5. By Distribution Channel
  • 9.3.4. South Korea Dry Eye Syndrome Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Indication
      • 9.3.4.2.2. By Product Type
      • 9.3.4.2.3. By Dosage Form
      • 9.3.4.2.4. By Type
      • 9.3.4.2.5. By Distribution Channel
  • 9.3.5. Australia Dry Eye Syndrome Treatment Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Indication
      • 9.3.5.2.2. By Product Type
      • 9.3.5.2.3. By Dosage Form
      • 9.3.5.2.4. By Type
      • 9.3.5.2.5. By Distribution Channel

10. South America Dry Eye Syndrome Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Product Type
  • 10.2.3. By Dosage Form
  • 10.2.4. By Type
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dry Eye Syndrome Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Product Type
      • 10.3.1.2.3. By Dosage Form
      • 10.3.1.2.4. By Type
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Argentina Dry Eye Syndrome Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Product Type
      • 10.3.2.2.3. By Dosage Form
      • 10.3.2.2.4. By Type
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Colombia Dry Eye Syndrome Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Product Type
      • 10.3.3.2.3. By Dosage Form
      • 10.3.3.2.4. By Type
      • 10.3.3.2.5. By Distribution Channel

11. Middle East and Africa Dry Eye Syndrome Treatment Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Indication
  • 11.2.2. By Product Type
  • 11.2.3. By Dosage Form
  • 11.2.4. By Type
  • 11.2.5. By Distribution Channel
  • 11.2.6. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Dry Eye Syndrome Treatment Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Indication
      • 11.3.1.2.2. By Product Type
      • 11.3.1.2.3. By Dosage Form
      • 11.3.1.2.4. By Type
      • 11.3.1.2.5. By Distribution Channel
  • 11.3.2. Saudi Arabia Dry Eye Syndrome Treatment Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Indication
      • 11.3.2.2.2. By Product Type
      • 11.3.2.2.3. By Dosage Form
      • 11.3.2.2.4. By Type
      • 11.3.2.2.5. By Distribution Channel
  • 11.3.3. UAE Dry Eye Syndrome Treatment Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Indication
      • 11.3.3.2.2. By Product Type
      • 11.3.3.2.3. By Dosage Form
      • 11.3.3.2.4. By Type
      • 11.3.3.2.5. By Distribution Channel

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Johnson & Johnson
  • 14.6.2. AbbVie Inc.
  • 14.6.3. Bausch Health Companies Inc.
  • 14.6.4. Novartis AG
  • 14.6.5. Sun Pharmaceuticals Industries Limited
  • 14.6.6. Santen Pharmaceutical Co., Ltd.
  • 14.6.7. Otsuka Pharmaceutical Co., Ltd.
  • 14.6.8. Oyster Point Pharma, Inc.
  • 14.6.9. Alcon Inc.
  • 14.6.10. GlaxoSmithKline plc.

15. Strategic Recommendations